Diego E. Bagnasco

Genoa, 16132, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 137 publications

Staphylococcus Aureus Toxins and Asthma: Pathophysiological Mechanisms, Clinical Relevance, and Therapeutic Implications in the Biologics Era.

Staphylococcus Aureus Toxins and Asthma: Pathophysiological Mechanisms, Clinical Relevance, and Therapeutic Implications in the Biologics Era.

Journal: Toxins

Published: July 02, 2026

Adherence to inhaled treatment is associated with better disease control and quality of life in mild-to-moderate asthma.

Adherence to inhaled treatment is associated with better disease control and quality of life in mild-to-moderate asthma.

Journal: Respiratory medicine

Published: June 16, 2026

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.

Journal: Journal of personalized medicine

Published: May 12, 2026

Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations.

Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations.

Journal: Expert opinion on drug safety

Published: May 11, 2026

Use of an Anti-Thymic Stromal Lymphopoietin Agent in Patients With Asthma and Clinically Significant Bronchiectasis: A Case Series.

Use of an Anti-Thymic Stromal Lymphopoietin Agent in Patients With Asthma and Clinically Significant Bronchiectasis: A Case Series.

Journal: Chest

Published: April 21, 2026

A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.

A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.

Journal: The World Allergy Organization journal

Published: April 08, 2026

Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years.

Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: March 21, 2026

The PEACE-24 study: Tezepelumab improves exercise tolerance and symptoms control in severe asthma.

The PEACE-24 study: Tezepelumab improves exercise tolerance and symptoms control in severe asthma.

Journal: Respiratory medicine

Published: February 26, 2026

New Insights in Respiratory Diseases.

New Insights in Respiratory Diseases.

Journal: Biomedicines

Published: February 10, 2026

Impact of Biologics Administered for Severe Asthma on T2-comorbidities: A Narrative Review.

Impact of Biologics Administered for Severe Asthma on T2-comorbidities: A Narrative Review.

Journal: Archivos de bronconeumologia

Published: January 28, 2026

Long-term effects of sublingual immunotherapy (SLIT) in preventing the development of asthma in allergic rhinitis: Revision of 15-year follow-up.

Long-term effects of sublingual immunotherapy (SLIT) in preventing the development of asthma in allergic rhinitis: Revision of 15-year follow-up.

Journal: The World Allergy Organization journal

Published: January 21, 2026

Modifying the course of asthma: mechanisms and strategies for clinical remission.

Modifying the course of asthma: mechanisms and strategies for clinical remission.

Journal: Current opinion in allergy and clinical immunology

Published: December 02, 2025

Showing 1-12 of 137

Last Updated: 09/26/2026